Obesity and cardiovascular disease: Role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system

Hormone Molecular Biology and Clinical Investigation

Volumn 15, Issue 2, 2013, Pages 49-57

  Lastra, Guido ^b   Sowers, James R ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Adipose tissue; Cardiovascular disease; Inflammation; Insulin resistance; Obesity; Overnutrition; Reninangiotensin aldosterone system

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; MACROPHAGE; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; COMPLICATION; IMMUNOLOGY; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INSULIN RESISTANCE; OBESITY; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84928649636     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0025     Document Type: Review

References (66)

1. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49. (Pubitemid 40712793)
2. Lastra G, Manrique C, Sowers J. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis 2006;13:365-73. (Pubitemid 44512240)
3. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-60. (Pubitemid 47529329)
4. Narayan K, Boyle J, Thompson T, Sorensen S, Williamson D. Lifetime risk for diabetes mellitus in the United States. J Am Med Assoc 2003;290:1884-90. (Pubitemid 37430605)
5. Lastra-Gonzalez G, Manrique C, Govindarajan G, Whaley-Connell A, Sowers J. Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin Pharmacother 2005;6:2209-21. (Pubitemid 41582208)
6. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P. Barth TFE, Dragun D, Skurk T, Hauner H, Blüher M, Unger T, Wolf A-M, Knippschild U, Hombach V, Marx N. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1304-10.
7. Wellen K, Hotamisligil G. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8. (Pubitemid 38063699)
8. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla L. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003;278:9850-5. (Pubitemid 36800488)
9. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7. (Pubitemid 30413663)
10. Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res 2001;33: 189-95. (Pubitemid 32452793)
11. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069-78.
12. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres J-P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-84.
13. Pantanetti P, Garrapa G, Mantero F, Boscaro M, Faloia E, Venarucci D. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens 2004;26:387-98. (Pubitemid 38685924)
14. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro M-C. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21: 2185-94. (Pubitemid 47026453)
15. Kalupahana N, Massiera F, Quignard-Boulange A, Ailhaud G, Voy B, Wasserman D, Moustaid-Moussa N. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2012;20:48-56.
16. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:H2009-23. (Pubitemid 47605846)
17. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003;42:31-8. (Pubitemid 36842233)
18. Eller K, Kirsch A, Wolf AM, Sopper S, Tagwerker A, Stanzl U, Wolf D, Patsch W, Rosenkranz AR, Eller P. Potential role of regulatory t cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011;60:2954-62.
19. Sowers JR. Diabetes mellitus and vascular disease. Hypertension 2013;61:943-7.
20. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin ii-induced hypertension and vascular injury. Hypertension 2011;57:469-76.
21. Ilan Y, Maron R, Tukpah, Maioli TU, Murugaiyan G, Yang K, Wu HY, Weiner HL. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010;107:9765-70.
22. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009;21:1105-11.
23. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012;59:324-30.
24. Chen X-L, Tummala PE, Olbrych MT, Alexander RW, Medford RM, Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9. (Pubitemid 28503085)
25. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10. (Pubitemid 35217013)
26. Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, Hayden MR, Wei Y, Ferrario C, Sowers JR. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008;295:E110-6.
27. Brown NJ. Aldosterone and Vascular Inflammation. Hypertension 2008;51:161-7. (Pubitemid 351159920)
28. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy P, Higaki J, Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999;17:537-45. (Pubitemid 29308564)
29. Calo LA, Zaghetto F, Pagnin E, Davis PA, de Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22phox in human mononuclear leukocytes. J Clin Endocrinol Metab 2004;89:1973-6. (Pubitemid 38507960)
30. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, Patel K, Ferrario C, Sowers JR. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009;150:2561-8.
31. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, Stas S, Kumar P, Sha Q, Ferrario CM, Sowers JR. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005;288:E353-9. (Pubitemid 40110643)
32. Luther J, Luo P, Kreger M, Brissova M, Dai C, Whitfield T, Kim H, Wasserman D, Powers A, Brown N. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011;54:2152-63.
33. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007;50:750-5. (Pubitemid 47442741)
34. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 2005;25:1142-7. (Pubitemid 40776600)
35. Pulakat L, Demarco V, Whaley-Connell A, Sowers J. The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 2011;1:102-12.
36. Pulakat L, DeMarco VG, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell A, Sowers JR. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol 2011;301:R885-95.
37. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol 2009;71:1-6.
38. Campión J, Maestro B, Mata FS, Dávila N, Carranza MC, Calle C. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J Steroid Biochem Mol Biol 1999;70:211-8. (Pubitemid 29528432)
39. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-63. (Pubitemid 44402119)
40. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006;91:454-9. (Pubitemid 43236909)
41. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, Motley ED, Eguchi S. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006;48:534-40. (Pubitemid 44843847)
42. Rossi G, Boscaro M, Ronconi V, Funder J. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005;16:104-7. (Pubitemid 40432459)
43. Bertrand L, Horman S, Beauloye C, Vanoverschelde A-M. Insulin signalling in the heart. Cardiovasc Res 2008;79:238-48. (Pubitemid 351951609)
44. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 2013;62:313-9.
45. DeMarco VG, Ford DA, Henriksen EJ, Aroor AR, Johnson MS, Habibi J, Ma L, Yang J, Albert CJ, Lally JW, Ford CA, Prasannarong M, Hayden MR, Whaley-Connell AT, Sowers JR. Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology 2013;154: 159-71.
46. Jung DY, Ko HJ, Lichtman EI, Lee, Lawton E, Ong H, Yu K, Azuma Y, Friedline RH, Lee KW, Kim JK. Short-term weight loss attenuates local tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese mice. Am J Physiol Endocrinol Metab 2013;304:E964-76.
47. Vieira VJ, Valentine RJ, Wilund KR, Antao N, Baynard T, Woods JA. Effects of exercise and low-fat diet on adipose tissue inflammation and metabolic complications in obese mice. Am J Physiol Endocrinol Metab 2009;296:E1164-71.
48. Tsai AC, Sandretto A, Chung Y-C. Dieting is more effective in reducing weight but exercise is more effective in reducing fat during the early phase of a weight-reducing program in healthy humans. J Nutr Biochem 2003;14:541-9. (Pubitemid 37162653)
49. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012;98:1763-77.
50. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003;23:1042-7. (Pubitemid 36713558)
51. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot J-L, Bouloumié A, Barbatelli G, Cinti S, Svensson P-A, Barsh GS, Zucker J-D, Basdevant A, Langin D, Clément K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgeryinduced weight loss. Diabetes 2005;54:2277-86. (Pubitemid 41134253)
52. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM, Weight loss and the renin-angiotensinaldosterone system. Hypertension 2005;45:356-62.
53. Ho J, Keogh J, Bornstein S, Ehrhart-Bornstein M, Lewis J, Clifton P, Torpy D. Moderate weight loss reduces renin and aldosterone but does not influence basal or stimulated pituitary-adrenal axis function. Horm Metab Res 2007;39:694-9. (Pubitemid 47492655)
54. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
55. Hansson L, Lindholm L, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg B, Wester P, Bjorck J. Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6. (Pubitemid 29087980)
56. Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, Michelson E, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66. (Pubitemid 37093915)
57. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288(23):2981-97.
58. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 2003;107:1291-6. (Pubitemid 36314413)
59. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlof B, for the LIFE Study Investigators. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007;50:984-90. (Pubitemid 350287545)
60. Bosch J, Yusuf S, Gerstein H, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman R. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62. (Pubitemid 44550032)
61. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
62. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
63. Swaminathan K, Davies J, George J, Rajendra N, Morris A, Struthers A. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008;51:762-8.
64. Davies J, Band M, Morris A, Struthers A. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47:1687-94. (Pubitemid 40022402)
65. Preiss D, Thomas LE, Sun J-L, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang F-T, Califf RM, McMurray JJ. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. BMJ Open 2012;2(6):e001925.
66. Hershon K. Mechanistic and clinical aspects of renin-angiotensin- aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract 2011;17:430-40.